• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Video

Rising Rates Won’t Slow Deal Flow Says Kellner Fund Manager

Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance.
By GREGG GREENBERG Jul 02, 2015 | 04:31 PM EDT
Stocks quotes in this article: GAKAX, TEVA, MYL, PRGO

Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance. And just because interest rates are ticking higher, don’t think the merger activity will slow down, said Chris Pultz, portfolio manager for the Kellner Merger Fund. The merger arbitrage business has a positive correlation to interest rates so as interest rates rise we will see an increase in our rates of return,' said Pultz. 'We have historically not seen any sort of dip in merger activity as interest rates rise.' Pultz oversees the Kellner Merger fund which has returned 3.3% so far in 2015. The fund does not speculate on potential deals, preferring to wait until a definitive agreement is announced before jumping in. 'We go long the target and short the acquirer and we lock in a spread. And what that does is give us a rate of return that is uncorrelated to the market. So regardless if the market goes up 20% or down 20%, as long as this deal closes we will lock in that spread,' said Pultz who added that he prefers larger deals because they offer more liquidity and the potential for larger spreads. One particular deal Pultz –and the rest of the merger arbitrage community is closely watching is the tangled dance between generic drugmakers Mylan, Perrigo and Teva Pharmaceuticals. 'I think Mylan is in a good position here,' said Pultz. 'Perrigo shareholders will probably benefit either from a Mylan deal, and I’m sure Perrigo is out there shopping themselves to other deals as well. And they are probably looking for a higher price from Mylan which I think we probably will get.' A lot of dealmaking is currently taking place in the healthcare and insurance sectors as a result of the Affordable Care Act.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

TAGS: Investing | Video | Technology | Interest Rates | Insurance | Mergers and Acquisitions | Healthcare | Executive Interview

More from Video

Amid the Selling, Here's the Big Question Now

James "Rev Shark" DePorre
Feb 25, 2021 4:43 PM EST

How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre
Oct 6, 2020 4:44 PM EDT

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich
Aug 25, 2020 1:11 PM EDT

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich
Dec 30, 2019 12:39 PM EST

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich
Oct 30, 2019 1:13 PM EDT

Breaking down an approach to the long side of this biotech stock.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login